The tumor suppressor interferon regulatory factor 1 interferes with SP1 activation to repress the human CDK2 promoter

Rong Lin Xie, Sunita Gupta, Angela Miele, Dov Shiffman, Janet L. Stein, Gary S. Stein, Andre J van Wijnen

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Cell growth control by interferons (IFNs) involves upregulation of the tumor suppressor interferon regulatory factor 1 (IRF1). To exert its anti-proliferative effects, this factor must ultimately control transcription of several key genes that regulate cell cycle progression. Here we show that the G1/S phase-related cyclin-dependent kinase 2 (CDK2) gene is a novel proliferation-related downstream target of IRF1. We find that IRF1, but not IRF2, IRF3, or IRF7, selectively represses CDK2 gene transcription in a dose- and time-dependent manner. We delineate the IRF1-responsive repressor element between nt -68 to -31 of the CDK2 promoter. For comparison, the tumor suppressor p53 represses CDK2 promoter activity independently of IRF1 through sequences upstream of nt -68, and the CDP/cut/Cuxl homeodomain protein represses transcription downstream of -31. Thus, IRF1 repression represents one of three distinct mechanisms to attenuate CDK2 levels. The -68/-31 segment lacks a canonical IRF responsive element but contains a single SP1 binding site. Mutation of this element abrogates SP1-dependent enhancement of CDK2 promoter activity as expected but also abolishes IRF1-mediated repression. Forced elevation of SP1 levels increases endogenous CDK2 levels, whereas IRF1 reduces both endogenous SP1 and CDK2 protein levels. Hence, IRF1 represses CDK2 gene expression by interfering with SP1-dependent transcriptional activation. Our findings establish a causal series of events that functionally connect the anti-proliferative effects of interferons with the IRF1-dependent suppression of the CDK2 gene, which encodes a key regulator of the G1/S phase transition.

Original languageEnglish (US)
Pages (from-to)26589-26596
Number of pages8
JournalJournal of Biological Chemistry
Volume278
Issue number29
DOIs
StatePublished - Jul 18 2003
Externally publishedYes

Fingerprint

Interferon Regulatory Factor-1
Cyclin-Dependent Kinase 2
Tumors
Chemical activation
Neoplasms
Transcription
Genes
G1 Phase
S Phase
Interferons
human CDK2 protein
Cytidine Diphosphate
Homeodomain Proteins
cdc Genes
Phase Transition
Cell growth
Gene expression
Transcriptional Activation
Up-Regulation
Phase transitions

ASJC Scopus subject areas

  • Biochemistry

Cite this

Xie, R. L., Gupta, S., Miele, A., Shiffman, D., Stein, J. L., Stein, G. S., & van Wijnen, A. J. (2003). The tumor suppressor interferon regulatory factor 1 interferes with SP1 activation to repress the human CDK2 promoter. Journal of Biological Chemistry, 278(29), 26589-26596. https://doi.org/10.1074/jbc.M301491200

The tumor suppressor interferon regulatory factor 1 interferes with SP1 activation to repress the human CDK2 promoter. / Xie, Rong Lin; Gupta, Sunita; Miele, Angela; Shiffman, Dov; Stein, Janet L.; Stein, Gary S.; van Wijnen, Andre J.

In: Journal of Biological Chemistry, Vol. 278, No. 29, 18.07.2003, p. 26589-26596.

Research output: Contribution to journalArticle

Xie, RL, Gupta, S, Miele, A, Shiffman, D, Stein, JL, Stein, GS & van Wijnen, AJ 2003, 'The tumor suppressor interferon regulatory factor 1 interferes with SP1 activation to repress the human CDK2 promoter', Journal of Biological Chemistry, vol. 278, no. 29, pp. 26589-26596. https://doi.org/10.1074/jbc.M301491200
Xie, Rong Lin ; Gupta, Sunita ; Miele, Angela ; Shiffman, Dov ; Stein, Janet L. ; Stein, Gary S. ; van Wijnen, Andre J. / The tumor suppressor interferon regulatory factor 1 interferes with SP1 activation to repress the human CDK2 promoter. In: Journal of Biological Chemistry. 2003 ; Vol. 278, No. 29. pp. 26589-26596.
@article{bc57f00de7894dd1a36c07be48b78e0c,
title = "The tumor suppressor interferon regulatory factor 1 interferes with SP1 activation to repress the human CDK2 promoter",
abstract = "Cell growth control by interferons (IFNs) involves upregulation of the tumor suppressor interferon regulatory factor 1 (IRF1). To exert its anti-proliferative effects, this factor must ultimately control transcription of several key genes that regulate cell cycle progression. Here we show that the G1/S phase-related cyclin-dependent kinase 2 (CDK2) gene is a novel proliferation-related downstream target of IRF1. We find that IRF1, but not IRF2, IRF3, or IRF7, selectively represses CDK2 gene transcription in a dose- and time-dependent manner. We delineate the IRF1-responsive repressor element between nt -68 to -31 of the CDK2 promoter. For comparison, the tumor suppressor p53 represses CDK2 promoter activity independently of IRF1 through sequences upstream of nt -68, and the CDP/cut/Cuxl homeodomain protein represses transcription downstream of -31. Thus, IRF1 repression represents one of three distinct mechanisms to attenuate CDK2 levels. The -68/-31 segment lacks a canonical IRF responsive element but contains a single SP1 binding site. Mutation of this element abrogates SP1-dependent enhancement of CDK2 promoter activity as expected but also abolishes IRF1-mediated repression. Forced elevation of SP1 levels increases endogenous CDK2 levels, whereas IRF1 reduces both endogenous SP1 and CDK2 protein levels. Hence, IRF1 represses CDK2 gene expression by interfering with SP1-dependent transcriptional activation. Our findings establish a causal series of events that functionally connect the anti-proliferative effects of interferons with the IRF1-dependent suppression of the CDK2 gene, which encodes a key regulator of the G1/S phase transition.",
author = "Xie, {Rong Lin} and Sunita Gupta and Angela Miele and Dov Shiffman and Stein, {Janet L.} and Stein, {Gary S.} and {van Wijnen}, {Andre J}",
year = "2003",
month = "7",
day = "18",
doi = "10.1074/jbc.M301491200",
language = "English (US)",
volume = "278",
pages = "26589--26596",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "29",

}

TY - JOUR

T1 - The tumor suppressor interferon regulatory factor 1 interferes with SP1 activation to repress the human CDK2 promoter

AU - Xie, Rong Lin

AU - Gupta, Sunita

AU - Miele, Angela

AU - Shiffman, Dov

AU - Stein, Janet L.

AU - Stein, Gary S.

AU - van Wijnen, Andre J

PY - 2003/7/18

Y1 - 2003/7/18

N2 - Cell growth control by interferons (IFNs) involves upregulation of the tumor suppressor interferon regulatory factor 1 (IRF1). To exert its anti-proliferative effects, this factor must ultimately control transcription of several key genes that regulate cell cycle progression. Here we show that the G1/S phase-related cyclin-dependent kinase 2 (CDK2) gene is a novel proliferation-related downstream target of IRF1. We find that IRF1, but not IRF2, IRF3, or IRF7, selectively represses CDK2 gene transcription in a dose- and time-dependent manner. We delineate the IRF1-responsive repressor element between nt -68 to -31 of the CDK2 promoter. For comparison, the tumor suppressor p53 represses CDK2 promoter activity independently of IRF1 through sequences upstream of nt -68, and the CDP/cut/Cuxl homeodomain protein represses transcription downstream of -31. Thus, IRF1 repression represents one of three distinct mechanisms to attenuate CDK2 levels. The -68/-31 segment lacks a canonical IRF responsive element but contains a single SP1 binding site. Mutation of this element abrogates SP1-dependent enhancement of CDK2 promoter activity as expected but also abolishes IRF1-mediated repression. Forced elevation of SP1 levels increases endogenous CDK2 levels, whereas IRF1 reduces both endogenous SP1 and CDK2 protein levels. Hence, IRF1 represses CDK2 gene expression by interfering with SP1-dependent transcriptional activation. Our findings establish a causal series of events that functionally connect the anti-proliferative effects of interferons with the IRF1-dependent suppression of the CDK2 gene, which encodes a key regulator of the G1/S phase transition.

AB - Cell growth control by interferons (IFNs) involves upregulation of the tumor suppressor interferon regulatory factor 1 (IRF1). To exert its anti-proliferative effects, this factor must ultimately control transcription of several key genes that regulate cell cycle progression. Here we show that the G1/S phase-related cyclin-dependent kinase 2 (CDK2) gene is a novel proliferation-related downstream target of IRF1. We find that IRF1, but not IRF2, IRF3, or IRF7, selectively represses CDK2 gene transcription in a dose- and time-dependent manner. We delineate the IRF1-responsive repressor element between nt -68 to -31 of the CDK2 promoter. For comparison, the tumor suppressor p53 represses CDK2 promoter activity independently of IRF1 through sequences upstream of nt -68, and the CDP/cut/Cuxl homeodomain protein represses transcription downstream of -31. Thus, IRF1 repression represents one of three distinct mechanisms to attenuate CDK2 levels. The -68/-31 segment lacks a canonical IRF responsive element but contains a single SP1 binding site. Mutation of this element abrogates SP1-dependent enhancement of CDK2 promoter activity as expected but also abolishes IRF1-mediated repression. Forced elevation of SP1 levels increases endogenous CDK2 levels, whereas IRF1 reduces both endogenous SP1 and CDK2 protein levels. Hence, IRF1 represses CDK2 gene expression by interfering with SP1-dependent transcriptional activation. Our findings establish a causal series of events that functionally connect the anti-proliferative effects of interferons with the IRF1-dependent suppression of the CDK2 gene, which encodes a key regulator of the G1/S phase transition.

UR - http://www.scopus.com/inward/record.url?scp=0038036023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038036023&partnerID=8YFLogxK

U2 - 10.1074/jbc.M301491200

DO - 10.1074/jbc.M301491200

M3 - Article

C2 - 12732645

AN - SCOPUS:0038036023

VL - 278

SP - 26589

EP - 26596

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 29

ER -